Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain.
Anticancer Drugs. 2011 Jun;22(5):477-9. doi: 10.1097/CAD.0b013e328344484b.
Pancreatic neuroendocrine tumors (PNETs) are rare malignancies that arise from the islets of Langerhans. The role of standard chemotherapy in advanced well-differentiated PNETs remains to be defined. Sunitinib is an oral multitargeted inhibitor with antiangiogenic and antitumor properties that has shown significant improvement in survival in metastatic PNETs, although objective responses by Response Evaluation Criteria in Solid Tumors were only 9%. We herein report on the case of a middle-aged woman with metastatic PNET who was heavily pretreated for her advanced disease with limited success, and who showed clinical, biochemical, and radiological responses by using Choi criteria but not Response Evaluation Criteria in Solid Tumors criteria. To our knowledge, this is the first reported case of treatment with sunitinib in a patient with PNET in response to Choi criteria.
胰腺神经内分泌肿瘤（PNETs）是一种罕见的恶性肿瘤，起源于胰岛。在晚期高分化 PNET 中，标准化疗的作用仍有待确定。舒尼替尼是一种口服多靶点抑制剂，具有抗血管生成和抗肿瘤特性，在转移性 PNET 中显示出显著的生存改善，尽管实体瘤反应评估标准的客观反应仅为 9%。我们在此报告一例转移性 PNET 的中年女性患者，她的晚期疾病经过大量预处理，但疗效有限，并且根据 Choi 标准而非实体瘤反应评估标准显示出临床、生化和影像学反应。据我们所知，这是首例报告的 PNET 患者使用舒尼替尼治疗并根据 Choi 标准应答的病例。
